CEFUROXIME SODIUM

CEFUROXIME SODIUM
(se-fyoor-ox'eem)
Zinacef
CEFUROXIME AXETIL
Ceftin
Classifications: antibiotic; second-generation cephalosporin;
Therapeutic: antibiotic
; cephalosporin
Prototype: Cefaclor
Pregnancy Category: B

Availability

125 mg, 250 mg, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g injection

Action

Semisynthetic second-generation cephalosporin beta-lactam antibiotic. Preferentially binds to one or more of the penicillin-binding proteins (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall synthesis, thus killing the bacterium.

Therapeutic Effect

Resistance against beta-lactamase–producing strains exceeds that of first-generation cephalosporins. Similar to other second-generation cephalosporins, cefuroxime is more active against gram-negative bacteria than are the first-generation cephalosporins but not as active as the third-generation cephalosporins.

Uses

Infections caused by susceptible organisms in the lower respiratory tract, urinary tract, skin, and skin structures; also used for treatment of meningitis, gonorrhea, and otitis media and for perioperative prophylaxis (e.g., open-heart surgery), early Lyme disease.

Contraindications

Hypersensitivity to cephalosporins and related antibiotics; viral infections.

Cautious Use

History of allergy, particularly to drugs; penicillin sensitivity; renal insufficiency; history of colitis or other GI disease; potent diuretics; pregnancy (category B), lactation.

Route & Dosage

Moderate to Severe Infections
Adult: PO 250–500 mg q12h IV/IM 750 mg–1.5 g q6–8h
Child (3 mo–12 y): PO 10–15 mg/kg (125–250 mg) q12h IV/IM 50–100 mg/kg/d divided q8h (max: 6 g/d)

Bacterial Meningitis
Adult: IV/IM 1.5–3 g q8h
Child/Infant (>3 mo): IV/IM 200–240 mg/kg/d divided q6–8h; reduced to 100 mg/kg/d upon improvement

Surgical Prophylaxis
Adult/Adolescent: IV/IM 1.5 g 30–60 min before surgery, then 750 mg q8h for 24 h

Renal Impairment
Clcr 10–20 mL/min: give q12h; <10 mL/min: give q24h


Hemodialysis: Give supplemental dose

Administration

Oral
  • Cefuroxime tablets and oral suspension are not substitutable on a mg-for-mg basis.
  • The oral suspension is for infants and children 3 mo to 12 y. Each teaspoon (5 mL) contains the equivalent of 125 mg cefuroxime. Shake oral suspension well before each use.
Intramuscular
  • Shake IM suspension gently before administration. IM injections should be made deeply into large muscle mass. Rotate injection sites.
Intravenous
  • IV administration to neonates, infants and children: Verify correct IV concentration and rate of infusion/injection with physician.

PREPARE: Direct: Dilute each 750 mg with 8 mL sterile water, D5W, or NS.  Intermittent: Further dilute in 50–100 mL of compatible solution.  Continuous: May be added to 1000 mL of IV compatible solution.  

ADMINISTER: Direct: Give slowly over 3–5 min.  Intermittent: Give over 30 min.  Continuous: Give over 6–24 h.  

INCOMPATIBILITIES Solution/additive: aminoglycosides, ciprofloxacin, ranitidine. Y-site: aminoglycosides, azithromycin, cisatracurium, clarithromycin, filgrastim, fluconazole, midazolam, vancomycin, vinorelbine.

  • Cefuroxime powder and solutions of the drug may range in color from light yellow to amber without adversely affecting product potency.
  • Store powder protected from light unless otherwise directed. After reconstitution, store suspension at 2°–30° C (36°–86° F). Discard after 10 d.

Adverse Effects (≥1%)

Body as a Whole: Thrombophlebitis (IV site); pain, burning, cellulitis (IM site); superinfections, positive Coombs' test. GI: Diarrhea, nausea, antibiotic-associated colitis. Skin: Rash, pruritus, urticaria. Urogenital: Increased serum creatinine and BUN, decreased creatinine clearance.

Diagnostic Test Interference

Cefuroxime causes false-positive (black-brown or green-brown color) urine glucose reaction with copper reduction reagents (e.g., Benedict's or Clinitest). but not with enzymatic glucose oxidase reagents (e.g., Clinistix, TesTape). False-positive direct Coombs' test (may interfere with cross-matching procedures and hematologic studies) has been reported.

Interactions

Drug: Probenecid decreases renal elimination of cefuroxime, thus prolonging its action.

Pharmacokinetics

Absorption: Well absorbed from GI tract; hydrolyzed to active drug in GI mucosa. Peak: PO 2 h; IM 30 min. Distribution: Widely distributed in body tissues and fluids; adequate CNS penetration with inflamed meninges; crosses placenta. Elimination: 66–100% in 24 h; in breast milk. Half-Life: 1–2 h.

Nursing Implications

Assessment & Drug Effects

  • Determine history of hypersensitivity reactions to cephalosporins, penicillins, and history of allergies, particularly to drugs, before therapy is initiated.
  • Lab tests: Perform culture and sensitivity tests before initiation of therapy and periodically during therapy if indicated. Therapy may be instituted pending test results. Monitor periodically BUN and creatinine clearance.
  • Inspect IM and IV injection sites frequently for signs of phlebitis.
  • Report onset of loose stools or diarrhea. Although pseudomembranous colitis (see Signs & Symptoms, Appendix F) rarely occurs, this potentially life-threatening complication should be ruled out as the cause of diarrhea during and after antibiotic therapy.
  • Monitor for manifestations of hypersensitivity (see Appendix F). Discontinue drug and report their appearance promptly.
  • Monitor I&O rates and pattern: Especially important in severely ill patients receiving high doses. Report any significant changes.

Patient & Family Education

  • Report loose stools or diarrhea promptly.
  • Report any signs or symptoms of hypersensitivity (see Appendix F).

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(140)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 05/02/2025 (0)
×
Wait 20 seconds...!!!